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Adeno-associated viruses (AAVs) have become highly promising tools for research and
clinical applications in the central nervous system (CNS). However, specific delivery of
genes to the cell type of interest is essential for the success of gene therapy and
therefore a correct selection of the promoter plays a very important role. Here, AAV8
vectors carrying enhanced green fluorescent protein (eGFP) as reporter gene under the
transcriptional control of different CNS-specific promoters were used and compared
with a strong ubiquitous promoter. Since one of the main limitations of AAV-mediated
gene delivery lies in its restricted cloning capacity, we focused our work on small-sized
promoters. We tested the transduction efficacy and specificity of each vector after
stereotactic injection into the mouse striatum. Three glia-specific AAV vectors were
generated using two truncated forms of the human promoter for glial fibrillar acidic protein
(GFAP) as well as a truncated form of the murine GFAP promoter. All three vectors
resulted in predominantly glial expression; however we also observed eGFP expression
in other cell-types such as oligodendrocytes, but never in neurons. In addition, robust
and neuron-specific eGFP expression was observed using the minimal promoters for
the neural protein BM88 and the neuronal nicotinic receptor β2 (CHRNB2). In summary,
we developed a set of AAV vectors designed for specific expression in cells of the CNS
using minimal promoters to drive gene expression when the size of the therapeutic gene
matters.
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INTRODUCTION
Longevity coincides with an increased prevalence in neurodegenerative disease and a concomitant
increase in the burden on health systems around the world (Checkoway et al., 2011). The need for
treatment options has fuelled research, with the field of gene therapy applied to central nervous
system (CNS) pathologies being on the forefront. Despite having recently witnessed a number of
major conceptual changes—such as gene delivery of specific transcription factors or micro-RNAs
for in vivo reprogramming of different cells to neurons (Caiazzo et al., 2011; Niu et al., 2013, 2015;
Colasante et al., 2015; Ghasemi-Kasman et al., 2015)—the more traditional approach of using viral
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vectors for the delivery of therapeutic genes still offers one of the
most promising options (Terzi and Zachariou, 2008; Bartus et al.,
2013; Kalia et al., 2015).
Although viral and non-viral vectors have been broadly used
for CNS gene therapy, viral vectors, including adeno-associated
viruses (AAVs) and lentiviruses (Blessing and Déglon, 2016),
are generally significantly more efficient than non-viral vectors
at delivering genes into the cells of interest (Nayerossadat
et al., 2012). Cell-specificity can be directed by either intrinsic
characteristics of the vector (Nayerossadat et al., 2012; Kantor
et al., 2014; Maguire et al., 2014) or the specificity of the promoter
that controls the expression of the transgene (Gray et al., 2011).
AAVs have emerged as the most promising tool for gene transfer
in the CNS (Klein et al., 2007; Aschauer et al., 2013; Bourdenx
et al., 2014) as they are able to transduce dividing and non-
dividing cells and induce stable, long-term gene expression in
the absence of inflammation and/or toxicity. Since neurons are
post-mitotic cells, the capability of AAV vectors to transduce
non-dividing cells is of vital importance in the context of
neurodegenerative disease gene therapy (Bartlett et al., 2008).
AAV serotype 8 (AAV8) in particular has been demonstrated
to be one of the most effective vectors in some structures of
the CNS, producing the highest rate of transgene transduction
in the striatum compared with other serotypes, in the absence
of neurotoxicity (Aschauer et al., 2013). Moreover, in a number
of studies in different animal models it was observed that this
serotype was actively transported along axons (Masamizu et al.,
2010, 2011; Aschauer et al., 2013; Löw et al., 2013). Due to its
small size (4.7 kb) one of its limitations is its cloning capacity,
however, the use of minimal specific promoters facilitates the
expression of larger genes or co-expression of more than one
gene from the same vector. In pre-clinical and clinical studies the
use of AAV as delivery vehicles was confirmed to result in robust
and long-term gene expression (reviewed by Hocquemiller et al.,
2016).
In the present work we describe the characterization of a
series of astrocyte- and neuron-specific small promoters in the
context of an AAV8 vector with the aim of using these vectors
for future therapeutic applications in neurodegenerative disease
including Parkinson‘s disease (Coune et al., 2012). Astrocytes
were chosen as they are one of the most abundant cell types in
the vertebrate CNS (Colombo and Farina, 2016) and contribute
to the pathogenesis of neurodegenerative disorders—hence they
may be an ideal cellular target for the delivery of therapeutic
genes (Pekny and Nilsson, 2005). Because the anatomy of the
striatum is affected in many neurodegenerative diseases, such
as Parkinson’s disease, we characterized the expression pattern
and specificity of the different vectors by stereotaxic injection
into the mouse striatum. Robust and specific neuronal transgene
expression was achieved using neuron-specific promoters, while
astrocyte-specific promoters drove expression in astrocytes and
oligodendrocytes but not in neurons.
MATERIALS AND METHODS
Animals and Stereotaxic AAV Injection
Eighteen C57BL/6 male mice (6–8 weeks old) were purchased
from Harlan Laboratories (Barcelona, Spain). Animal handling
was conducted in accordance with the European Council
Directive 2010/63/UE, as well as in agreement with the “Policy
on the Use of Animals in Neuroscience Research” issued by the
Society for Neuroscience. The experimental design was approved
by the Ethical Committee for Animal Testing of the University of
Navarra (protocol Ref: 102-16). Animal handling was conducted
in accordance with the European Council Directive 2010/63/UE,
as well as in agreement with the “Policy on the Use of Animals in
Neuroscience Research” issued by the Society for Neuroscience.
The experimental design was approved by the Ethical Committee
for Animal Testing of the University of Navarra (protocol Ref:
102-16). Anesthesia was induced by intraperitoneal injection of
ketamine (100 mg/kg) and xylazine (10 mg/kg). The coordinates
for targeting the striatum were 0.5mm rostral, 2mm lateral
and 3.5mm ventral from the bregma (Paxinos et al., 2001). All
animals received two pressure injections: one of 2µl of PBS/5%
sucrose containing AAV vector on the left side (4 × 109 vp),
and a second of vehicle alone on the right side of the striatum.
Injections were performed using a Hamilton syringe driven by a
syringe pump at a flow rate of 0.2µl/min. Following the injection,
the needle was left in place for 2min prior to being slowly
retracted to avoid vector leakage from the injection tract. After
surgery, animals were kept under constant monitoring with ad
libitum access to food and water.
Cells
Human embryonic kidney fibroblast (HEK-293) cells, were
purchased from the ATCC and were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (FBS), penicillin
(100µg/ml), and streptomycin (100U/ml) (all supplements were
from Invitrogen, Pisley, Scotland, UK). Cells were maintained at
37◦C in a humidified atmosphere of 5% CO2.
Plasmids
cDNA encoding enhanced green fluorescent protein (eGFP)
was isolated from the vector pBSKII-CMV-EGFP and inserted
into the multiple cloning site (MCS) of an rAAV2 plasmid,
which contained AAV2 inverted terminal repeats (ITR), to
obtain rAAV2-eGFP. Upstream of the eGFP coding sequence
different promoters were inserted: a constitutive hybrid promoter
composed of the CMV immediate-early enhancer fused to
chicken ß-actin promoter (CAG pr; Niwa et al., 1991), two
reduced versions of the human glial fibrillar acidic protein
(GFAP) promoter (hGFAP pr, 587 bp, containing the A, B, C1,
and D elements) (Lee et al., 2008) and hGFAP1D (512 bp),
in which the D sequence of was removed. This sequence was
previously shown to play an important role in the functionality
of the promoter (Besnard et al., 1991). Furthermore, using
the structure of the human gfaABC1D promoter and the
sequence of the murine GFAP promoter, a reduced version
of the murine gfaABC1D promoter was constructed (581 bp,
mGFAP pr). The proximal promoter of murine BM88 (88 bp;
Papadodima et al., 2005) and the minimal promoter driving
neuron-specific expression of the ß2 subunit of the nicotine
acetylcholine receptor (CHNRB2 pr, 177 bp; Bessis et al.,
1995), were used for neuron-specific targeting. Moreover, the
human growth hormone (hGH) poly A signal and the ß-globin
Frontiers in Neuroanatomy | www.frontiersin.org 2 February 2017 | Volume 11 | Article 2
Pignataro et al. AAV Vectors for CNS Delivery
intron were cloned into the plasmid (Figure 1). Minipreps and
maxipreps were prepared using commercial kits according to the
manufacturer’s instructions (Macherey-Nagel, Düren, Germany).
In order to study the functionality of the constructs, HEK-293T
cells were transfected with plasmid DNA using Lipofectamine
2000 reagent (Invitrogen, ThermoFisher Scientific, Waltham,
MA, USA). Transfections were performed according to the
manufacturer’s protocols. 1–2 µg of plasmid was transfected,
depending on the size of the culture plate used (6- or 12-wells).
Expression was analyzed 24–48 h post-transfection (hpt) under
a microscope equipped with epifluorescent illumination (Nikon
Eclipse 800).
Viral Vector Production
Recombinant single-stranded AAV8 vectors were purified from
HEK-293T cells that had been co-transfected using linear
polyethylenimine 25 kDa (Polysciences, Warrington, PA, USA)
with two different plasmids: a plasmid containing ITR-flanked
transgene constructs and a plasmid containing the adenoviral
helper genes plus AAV2 rep and AAV8 cap (named pDP8.ape,
Plasmid Factory, Bielefeld, Germany) as described (Durocher
et al., 2002). Seventy-two hpt the supernatant was collected
and treated with polyethylene glycol solution (PEG8000, 8% v/v
final concentration) for 48–72 h at 4◦C. Supernatant was then
centrifuged at 3000 rpm for 15 min. Pellet containing particles
from the supernatant was resuspended in lysis buffer and kept
at −80◦C. Cells containing AAV particles were collected and
treated with lysis buffer (50mM Tris-Cl, 150mM NaCl, 2mM
MgCl2, 0.1% Triton X-100) and kept at −80
◦C. Three cycles of
freezing and thawing were applied to both supernatant and cell
lysate. Viral particles obtained from cell supernatant and lysate
were purified by ultracentrifugation in an iodioxanol gradient
according to the method of Zolotukhin et al. (1999). The viral
batches were then concentrated further by passage through
centricon tubes (YM-100; Millipore, Bedford, MA). All vector
stocks were kept at−80◦C until used.
AAV vector titers (viral particles (vp)/ml) were determined
by quantitative PCR for viral genome copies extracted from
DNAase-treated viral particles (High Pure Viral Nucleic Acid
Kit, Roche). The primers used in the q-PCR were Forward-
eGFP: 5′-GTCCGCCCTGAGCAAACA-3′ and Reverse-eGFP:
5′-TCCAGCAGGACCATGTGATC-3′. Vector titers obtained
ranged from 2× 1012 to 9× 1012 vp/ml.
Histological Procedures
Mice were sacrificed 3 weeks post-surgery by transcardiac
perfusion with saline Ringer solution followed by 4%
paraformaldehyde in 0.1 M phosphate buffer (PB). Brains
were dissected and stored for 48 h in a cryopreservation solution
containing 10% glycerin and 2% dimethylsulphoxide (DMSO)
in 0.125 M PB, pH 7.4 at 4◦C. Frozen serial coronal sections (40
µm thickness) were obtained using a sliding microtome and
collected in cryopreservation solution in series of 10 adjacent
sections.
Free-floating sections were rinsed with Tris buffer pH 7.4
(TBS) and then incubated in a blocking solution containing 1%
cold fish gelatin (Sigma), 1% bovine serum albumin (BSA), and
0.05% Triton X-100 in TBS for 1 h; sections were then incubated
overnight at room temperature (RT), with the appropriate
primary antibodies diluted in blocking solution.
The following primary antibodies were used in double
immunofluorescent stains: (1) rabbit anti-GFAP (1:400, Dako,
Glostrup, Denmark; catalog number Z0334). (2) Mouse anti-
GFAP 1:400, AbD Serotec, Killington, UK; catalog number
4650-0309). (3) Mouse anti-neuronal nuclear antigen (NeuN;
1:500, Millipore, Darmstadt, Germany; catalog number MAB
377). (4) Goat anti-olig2 (1:200, R&D systems, Minneapolis,
MN; catalog number AF2418). (5) Rabbit anti-Iba1 (1:500,
Wako, Neuss, Germany; catalog number 019-19741). After
rinsing with TBS, sections were incubated with the appropriate
fluorescent secondary antibodies diluted as before for 1 h.
The following secondary antibodies were used (all purchased
from Molecular Probes and used 1:200): Alexa Fluor R© 633
donkey anti-rabbit IgG (#A21070), Alexa Fluor R© 633 donkey
anti-mouse IgG (#A21050); Alexa Fluor R© 546 donkey anti-
mouse IgG (#A10036); Alexa Fluor R© 633 donkey anti-goat IgG
(#A21080); Alexa Fluor R© 555 donkey anti-rabbit IgG (#A31572),
Alexa Fluor R© 546 goat anti-rabbit (#A11010) Alexa Fluor R©
546 goat anti-mouse (#A11003). Finally, sections were rinsed
in PBS and mounted on SuperFrost Ultra Plus slides, dried
at RT and coverslipped with Depex (VWR International). As
negative control and to verify the specificity of the secondary
antibodies, the same immunohistochemistry procedure was
performed omitting the primary antibodies. No staining was
observed. Furthermore, all antibodies used here were used in
other publications (see Eng et al., 2000; Talbott et al., 2007;
Gil-Perotin et al., 2009; Lalancette-Hebert et al., 2012; Seto
et al., 2014; Haberl et al., 2015). Sections were inspected under
a confocal laser-scanning microscope (LSM 800; Zeiss, Jena,
Germany). To ensure appropriate visualization of the labeled
elements and to avoid false positive results, the emission from
the argon laser at 488 nm was filtered through a band pass
filter of 505–530 nm and color-coded in green. The emission
following excitation from the helium laser at 543 nm was filtered
through a band pass filter of 560–615 nm and color-coded in
red. A long-pass filter of 650 nm was used to visualize the
emission from the helium laser at 633 nm and color-coded in pale
blue.
As the main goal of this study was to determine the
specificity of the chosen promoters in the context of AAV8-
mediated gene delivery to the striatum, we focused our
analysis on the transduced area only. The numbers of eGFP-
positive cells infected with each vector were determined
on images of eight random areas within the transduced
striatum regions (i.e., containing at least one eGFP+ cell)
per mouse using a 40x objective and ImageJ software.
Percentages were calculated based on the total number of
transduced cells (number of eGFP+NeuN+/total NeunN+,
eGFP+GFAP+/total GFAP+, or eGFP+Olig2+/total Olig2+,
respectively).
Statistical Analysis
The results were expressed as mean ± standard deviation
(SD). Statistical analyses were performed using the software
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FIGURE 1 | Schematic representation of the genomic structures of the AAV vectors. AAV vectors carrying reduced versions of the human or murine
astrocyte-specific GFAP promoters, the minimal neuronal promoters BM88 or CHNRB2, which control the expression of the reporter gene enhanced GFP (eGFP). The
expression cassettes also contain the ß-globin intron downstream of the promoter sequence and the human growth hormone polyadenylation signal sequence
(hGH-polyA).
FIGURE 2 | All plasmid constructs are functional in vitro. HEK-293T cells were transfected with the same amount of each plasmid and 48 h later eGFP
expression was analyzed. All promoters were able to drive transgene expression, the strongest one being BM88 and the weakest one hGFAP. As positive control, cells
were transfected with a plasmid expressing GFP under the control of the strong and ubiquitous promoter CAG.
GraphPadPrism. To test for difference in transduction efficacy,
a non-parametric one-way ANOVA with Tukey post-test was
applied, except for Figure 5 where we used Chi square analysis.
All tests were considered significant if p< 0.05.
RESULTS
In Vitro Analysis
A total of six recombinant AAV genomes carrying an eGFP
reporter gene were constructed (Figure 1; for a more detailed
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FIGURE 3 | Analysis of the transduction efficacy of the AAV8 vectors
carrying different promoters. Mice were treated with the different vectors (4
× 109 vp/mouse) by stereotaxic surgery in the left striatum. Twenty-one days
later mice were sacrificed and the number of eGFP-positive cells in the
transduced area was quantified (mGFAP = 648 cells; hGFAP = 360 cells;
hGFAP1D = 365 cells; BM88 = 808 cells; CHRNB2 = 204 cells; CAG =525
cells). Mean ± SD are shown. Differences in the number or GFP+ cells were
statistically evaluated by One-way ANOVA. Results were considered significant
when p < 0.05 and levels of significance are indicated as follows: *p < 0.05;
**p < 0.01; ***p < 0.001.
description of the vectors see Section Materials and Methods).
In brief, five constructs carried CNS cell-specific promoters and
one a ubiquitous promoter, CAG pr, which was used as control.
Three promoters targeting astrocytes were tested: hGFAP pr,
hGFAP1D pr, and mGFAP pr, as well as two neuronal ones,
BM88 pr and CHNRB2 pr. The expression of eGFP, driven by
the different constructs, was first analyzed in vitro by plasmid
transfection of HEK-293T cells (Figure 2). All promoters were
able to drive the expression of the fluorescent protein, however,
important differences in their transcriptional activity were found.
Of the neuronal promoters, BM88 was stronger than CHNRB2,
while the astrocyte promotermGFAPwas better than hGFAP, and
the level of eGFP expression was not diminished upon deletion
of the D region. Non-transfected controls were eGFP negative
whereas the majority of cells transfected with plasmid containing
eGFP under the control of CAG pr were strongly positive.
Analysis of the Transduction Efficacy of the
Different Vectors in Mouse Striatum
After testing the functionality of the different plasmids in vitro,
we produced the recombinant AAV8 vectors for in vivo studies.
A dose of 4× 109 vp of each AAV8-eGFP vector was injected into
the left striatum by stereotactic injection (n = 3 per group). The
mice did not display any adverse reaction or behavioral changes
after the intracranial surgery or during the subsequent period
until sacrifice. However, no long term studies were performed
to test the potential toxicity of sustained transgene expression.
Three weeks after vector injection mice were euthanized and
eGFP expression was analyzed in both the right and left striatum.
In all groups eGFP expression was detected in the left striatum
as well as along the injection tract but never in the right
brain hemisphere (See Supplementary Figure 1). The number
of eGFP-positive cells/µm2 varied depending on the promoter.
The highest number of transduced cells was observed with
the vector carrying the neuron-specific promoter BM88 pr
(Figure 3). Transduction was significantly less efficient using the
three variants of GFAP, CHNRB2, or CAG as promoter. The
lowest levels of expression were consistently found with the
construct containing CHRNB2 pr.
Transduction of Neurons and Astrocytes by
CAG-Driven AAV8
CNS tissue is highly heterogeneous and consists of different
cell types including neurons and glia cells. Following the
delivery of eGFP expressing vectors under the control of the
constitutive promoter CAG, eGFP-expressing cells with different
morphologies were observed. To further identify the type(s)
of cells transduced by this vector, a triple immunofluorescence
stain using both anti-eGFP as well as cell-specific markers was
performed. Astrocytes were identified by their expression of
GFAP, whereas for neurons the pan-neuronal marker of neuronal
nuclei (NeuN) was used (Figure 4). AAV8-CAG-eGFP mainly
transduced neuronal cells and to a lesser extent also astrocytes
and oligodendrocytes. Quantification of eGFP-expressing cells
revealed that the number of eGFP-positive neuronal cells was
eight-fold higher than the number of astrocytes (Figure 5). These
results indicate that both neurons and astrocytes are transduced
by AAV8 after stereotactic injection into the striatum, albeit with
a greatly varying efficacy.
Astrocytic Transgene Expression is Driven
by GFAP Promoters
Next we wanted to analyze the specificity of the vectors
containing either neuron or astrocyte-specific promoters. Inmice
injected with either of the AAV-GFAPpr variants most of the
eGFP-positive cells were astrocytes (Figure 6), while neurons
were never found to express eGFP (Figure 7). Interestingly, a
population of eGFP-positive cells lacking GFAP expression was
detected. These cells were lacking the morphological features
that typically characterize astrocytes and their small size and
morphology were consistent with an oligodendroglial phenotype.
In an attempt to properly identify the exact nature of these
cells, we labeled brain sections with anti-eGFP, anti-Olig 2, an
oligodendroglial marker, and anti-Ibal, a microglial marker. As
shown in Figure 8, eGFP co-localized with Olig2-expressing cells
but not with Ibal.
Mice injected with the vector carrying the mGFAP promoter
had the highest levels of transduction. A strong fluorescence was
observed in cell bodies throughout the dorsal area of the striatum.
Furthermore, the number of positive cells was similar in the
groups injected with either hGFAP or hGFAP1D, indicating that
the D element is dispensable for the transcriptional activity of
the promoter (no significant difference was observed between
these two promoters; Figure 9A). This is in line with what
was suggested by our in vitro results. Three weeks after viral
injection, 81.5% of astrocytes in AAV8-mGFAP recipients were
eGFP positive. With 55.5% of positive cells in AAV8-hGFAP- and
AAV8-hGFAP1D-injected mice, respectively, these promoters
were less efficient (Figure 9A). Moreover, co-localization of
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FIGURE 4 | AAV8 expressing eGFP under the control of an ubiquitous promoter transduce both neurons and astrocytes efficiently. Adult mice were
injected with 4 × 109 vp/mouse and killed 3 weeks post-injection to determine eGFP+cells (green) in the striatum. Neurons were labeled with an anti-NeuN antibody
(blue) and astrocytes were labeled with an anti-GFAP antibody (red). Arrows indicate eGFP double-positive cells (yellow = eGFP+/GFAP+, white GFP+/NeuN+).
Scale bars 20µm (A–D) and 5µm (E-H).
reporter gene expression and the oligodendrogliamarker Olig2 in
the AAV8-mGFAP group was the lowest with 17.4% (Figure 9B).
With the other variants 20% (AAV8-hGFAP1D) and 26.6%
(AAV8-hGFAP), respectively, stained positive for both eGFP and
Olig2. These results indicate that the mGFAP promoter works
best for astrocyte-specific transgene expression.
CHB2RN and BM88 Promoters Induce
Neuronal Transgene Expression
Selective neuronal transduction was observed in mice having
received the vector in which eGFP had been placed under control
of the CHNRB2 or BM88 promoters (Figure 10). Widespread
expression of the transgene was observed throughout the dorsal
region of the striatum. At higher magnification specific eGFP
expression was identified within NeuN-positive cells (Figure 10),
suggesting that eGFP-expressing cells accounted for a neuronal
phenotype. This is supported by the fact that co-localization of
eGFP and GFAP was never found. The percentage of NeuN-
positive cells co-expressing eGFP was significantly higher in
animals injected with the BM88 vector (63.4%) than in those
injected with the CHNRB2 promoter (15.9%), thus identifying
the former as the more useful one for expressing transgenes in
neuronal cells (Figure 11).
DISCUSSION
Here, we described the development and transduction efficacy
of AAV-based gene delivery vectors for cell-specific transgene
expression in the CNS.
FIGURE 5 | Quantitative analysis of AAV-CAG-eGFP transduction.
Although the AAV8 vector transduces both neurons and astrocytes and CAG
is a ubiquitous promoter, neuronal cells are transduced significantly better.
(Neurons = 1311/1577 eGFP+; astrocytes = 180/1577 eGFP+;
oligodendrocytes = 86/1577 eGFP+). Mean ± SD are shown. Analysis was
restricted to the transduced area of the striatum as described in Methods.
Differences in the number of eGFP+ cells were statistically evaluated by Chi
square analysis. Results were considered significant when p < 0.05;
***p < 0.001.
In order to achieve a successful delivery and expression of
the therapeutic gene, selection of both delivery vehicle and an
optimal expression cassette is essential. As vehicle we chose
AAV serotype 8 as it was previously shown to more efficiently
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FIGURE 6 | Analysis of brain transduction by AAV8 carrying eGFP under the transcriptional control of astrocyte-specific promoters. Mice were treated
with the different vectors carrying astrocyte-specific promoters mGFAP pr (A–C), hGFAP pr (D–F), and hGFAP1D pr (G–I) at the same dose by stereotaxic surgery in
the left striatum. Twenty-one days later mice were sacrificed and the number and type of eGFP+ cells (green) were analyzed. Astrocytes were labeled with an
anti-GFAP antibody (red). A clear co-localization of GFAP and transgene expression is indicated by arrows. Scale bars 20 µm.
transduce cells of the CNS than other serotypes (Aschauer
et al., 2013) and to also infect a larger area than the best
described and most commonly used serotype 2 (Watakabe
et al., 2015). The packaging capacity of serotypes 2 and 8
(or any other AAV serotype) does not differ and expression
cassettes are generally based on AAV2. However, having by far
the smallest packaging capacity amongst the viruses used for
gene therapy (4.4–4.7 kb), a need for a reduction in promoter
elements is obvious in order to allow the packaging of larger
genes or multiple genes. Accordingly we here focused on the
identification of small orminimal cell-specific promoters for CNS
applications.
The functionality of the newly generated plasmids was
first characterized in vitro by transfection into HEK-293T cell
lines. Although derived from human embryonic kidney cells,
previous reports demonstrated that this cell line expresses
significant amounts of proteins found in the CNS, such
as neurofibroblast subunits and α-internexin (Shaw et al.,
2002). HEK-293T cells also express different neuronal receptors
and electrophysiological studies have shown the presence of
endogenous voltage-activated ion currents (Shaw et al., 2002),
which supports the use of this cell line for testing the
performance of the CNS-specific promoters.We indeed observed
that all the “cell-specific” promoters were able to drive the
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FIGURE 7 | No transgene expression in neurons is detected when using AAV8 carrying GFAP derived promoters. NeuN expression (red) did not co-localize
with eGFP expression (green) after injection with AAV8 carrying the mGFAP (A–C), hGFAP (D–F), and hGFAP1D (G–I) promoters. Scale bars: low magnification—20
µm (A–I) and high magnification—5 µm (A′–I′).
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FIGURE 8 | AAV8 carrying GFAP-derived promoters drive transgene expression in oligodendrocytes. Brain sections were labeled with anti-Olig2 (red; upper
and middle panels) or anti-Iba1 (red; lower panels) and anti-GFAP (blue) to differentiate microglial, oligodendrocytes and macroglial. Olig2 immunoreactive cells (D,H)
and astrocytes (D,H,L) showed co-expression of eGFP (green; arrows: yellow = GFP+/GFAP+, white = GFP+/Olig2+) while Iba1-positive cells were negative. Scale
bars 20 µm (A–D) and 5 µm (E–L).
expression of the reporter gene. That the transduction of
HEK293T cells with AAV carrying the neuron-specific promoter
BM88 was significantly more efficient than with all other
promoters—including the ubiquitous promoter CAG—is easily
explained by the fact that the observed expression pattern of
CNS-specific proteins in HEK-293T cells is similar to that
of a typical early differentiating neurons or neuronal stem
cells.
AAV8 has been described to be highly efficient in driving eGFP
expression in astrocytes and neurons in the striatum (Taymans
et al., 2007) and we first tested the transduction efficiency and
efficacy of an eGFP-expressing AAV8 vector under the control
of the ubiquitous and highly potent promoter CAG. After
stereotactic delivery into the mouse striatum both astrocytes and
neurons were found to be transduced with our vector, the latter
even more efficiently.
Interestingly, previous experiments using an AAV8 with a
similar construct showed a better performance for astrocyte-
rather than neuronal transduction in the striatum (Aschauer
et al., 2013). Using a ubiquitous promotor in macaques resulted
in transduction of certain neuronal cell subtypes but not glia
(Masamizu et al., 2010). The main difference between our study
and that of Aschauer et al. is that they purified the AAV vector by
CsCl density gradient centrifugation, whereas we here performed
an iodixanol gradient. Differences in transduction-efficacy and
-specificity were shown previously to not only depend on the
AAV capsid serotype but to also be related to the production and
purification methods (Ayuso et al., 2010).
Astrocytes are the most abundant cell type in the vertebrate
CNS and hence involved in many degenerative diseases. We
therefore characterized reduced forms of the human and murine
GFAP promoters, which mainly drive transgene expression
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FIGURE 9 | Quantification of the percentage of eGFP+ astrocytes and oligodendrocytes transduced by AAV8 carrying GFAP-derived promoters. (A)
The vast majority of transgene expressing cells after AAV-GFAP-eGFP injection were astrocytes. The percentage of eGFP+ astrocytes/total GFAP+ cells is plotted
(mGFAP = 550/648 cells; hGFAP = 206/360 cells; hGFAP1D = 98/186 cells; CAG = 28/224 cells). (B) A smaller fraction of oligodendrocytes was eGFP+ (mGFAP =
22/131 cells; hGFAP = 41/157 cells; hGFAP1D = 40/186 cells; CAG = 16/224 cells). Mean ± SD are shown. Counting was restricted to the transduced area of the
striatum as described in Methods. Differences in the number of eGFP+ cells were statistically evaluated by One-way ANOVA. Results were considered p < 0.05 and
levels of significance are indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 10 | Analysis of brain transduction by AAV8 carrying eGFP under the transcriptional control of neuronal promoters. Mice were treated with AAV8
carrying the neuronal promoters BM88 (A–E), CHB2RN (F–J) and the eGFP reporter gene as before. Twenty-one days later mice were sacrificed and the number and
type of eGFP+ cells was analyzed. NeuN+ cells (red) showed a clear co-expression of eGFP (green; arrows), while astrocytes expressing GFAP (blue) did not express
eGFP (green). We also observed NeuN+ neurons that were not expressing eGFP. Scale bars: D, I 20µm. All others 50 µm.
in astrocytes. Importantly, because GFAP is not expressed in
neurons, these promoters cannot drive neuronal expression of
the transgene. The reduced form of the hGFAP promoter used
in this study was previously characterized in vitro by Lee et al.
(2008). We further reduced its size by removing the D element
located at the 3′ end of the promoter sequence. Deletion of
the D element was reported to severely reduce transcription
(Besnard et al., 1991; Lee et al., 2008), however, our in vivo data
indicates that this element is not essential for the transcriptional
activity of the promoter in astrocytes. In addition we tested the
transcriptional activity of the reduced version of the mGFAP
promoter, which was designed using the reduced version of the
hGFAP (Lee et al., 2008) as a model. The murine version of the
promoter was more active and specific than the human one.
Co-localization of eGFP/GFAP was observed in the striatum
of all mice injected with either of the three GFAP promoters,
demonstrating that they all efficiently transduce astrocytes. We
also found a proportion of eGFP-expressing GFAP-negative cells
that were subsequently identified as oligodendrocytes. Previous
work reported weak neuronal expression using GFAP promoter,
but oligodendrocyte expression has not been reported (Lee
et al., 2008). Currently we do not have an explanation for this
finding. Even though expression of hGFAP (but not mGFAP)
was shown in an oligodendrocyte precursor cell (Casper and
McCarthy, 2006), the infection and subsequent maturation of
these precursors can be excluded as the same precursor can
give rise to neuronal cells and eGFP expression was not seen
in either neurons or microglial cells. Interestingly, while the
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FIGURE 11 | Quantification of the percentage of neuronal cells
expressing eGFP after AAV8 injection carrying BM88 and CHB2RN
promoters. A high percentage of neuronal cells are transduced using the
minimal promoter BM88, higher neuronal transduction efficiency was obtained
in comparison to CHBRN and CAG promoters. The percentage of
eGFP+neurons/total NeuN+ cells is shown (BM88 = 808/1302 cells;
CHRNB2 = 204/1250 cells; CAG = 473/525 cells). Mean ± SD are plotted.
Counting was restricted to the transduced area of the striatum as described in
Methods and differences in the number or eGFP+ cells were statistically
evaluated by One-way ANOVA. The significance level was set to ***p < 0.001.
transduction efficacy of astrocytes was significantly better with
the murine GFAP promoter, transduction of oligodendrocytes
did not significantly differ between the three GFAP
variants.
While we observed a degree of axonal transport of both AAVs,
more experiments need to be performed to determine whether
this was retrograde or anterograde. In mice, vector transport
along astrocytes has been described in previous studies and was
found to be serotype dependent (anterograde: AAV2, Salegio
et al., 2012; retrograde: AAV5, Aschauer et al., 2013). Other
studies done in marmoset and macaque using AAV8 revealed
preferential retrograde transport of this serotype (Masamizu
et al., 2011). Future experiments will allow us to confirm the
direction of the axonal transport. Another of our future aims is
to use GFAP promoters for the astrocyte-selective expression of
genes coding for several transcription factors with the ultimate
goal of conducting in vivo-reprogramming of these astrocytes
into neurons.
For neuron-specific expression we used two very small
promoters with different transcriptional potencies, BM88 and
CHNB2. The minimal promoter derived from the neural
protein BM88 had a stronger transcriptional activity and in the
transduced area up to 63% of striatal neurons were eGFP+. This
can be explained by the expression pattern of BM88: it is not only
widely expressed in proliferating neuronal precursors, but also
at an even higher level in their post-mitotic neuronal progeny
in the developing as well as in the adult brain (Koutmani et al.,
2004). In contrast, the minimal CHRNB2 promoter was also
neuron specific but transgene expression was a lot lower and
found in only <20% of NeuN+ cells. This result was somehow
surprising since the CHNB2 pr controls the expression of the
nicotinic receptor β-subunit, which is expressed in themajority of
neurons in the brain. However, it can possibly be explained by the
fact that we are using a reduced version of the promoter, whose
activity is significantly lower than that of the original promoter
(Bessis et al., 1995). Thus we aremost likely unable to detect eGFP
expression in all the cells that have been transduced. Moreover,
the distribution of the nicotinic acetylcholine receptors subtypes
expressed in the CNS will have a direct effect on the promoter
activity (Gotti et al., 2006). Additional studies will be needed to
better characterize of the type of neurons transduced by either
promoter. The small size of these promoters allows the expression
of larger genes or more than one gene in neurons. Diseases
caused by the deficiency of large genes are not uncommon among
the spectrum of neurological disorders, such as for instance
in autism spectrum disorders, intellectual disability, or Dravet
syndrome, in which mutations in several genes are involved.
Thus, development of vectors allowing the insertion of multiple
genes would be of paramount importance for the adequate
development of gene therapy approaches when dealing with these
diseases.
In conclusion, we have developed and characterized AAV-
vectors with a relatively large cloning capacity for the cell-
specific delivery of therapeutic genes to the CNS. Albeit
yet needing further characterization these cell-specific AAVs
represent promising tools with a great potential use for the
development of gene therapy approaches for neurodegenerative
disorders.
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